Comments like this don't do anything to help the sp. The price has been stable and fluctuates with the market and fear that shorts interject. What I heard from this call that there are dedicated teams working on clinical, financial, and marketing and are rolling with the requirements. Very positive forward momentum on many fronts. I'm glad Nadar is insisting on following the approval protocol and will provide solid data that cannot be disputed when released. May take a bit longer but it is going to be well worth it. How quickly people forget .26 per share just a few months ago. I am very much appreciative where the price is now.
People want this to run as exactly planned and when there is a correction or detour, they use it to blast the company and it's CEO. I wish my life ran as planned as some here expect this company to do.
I'm finished with my soapbox now. We return to regularly scheduled commenting.
IMO